HighTower Advisors LLC Invests $268,000 in OrthoPediatrics Corp. (NASDAQ:KIDS)

HighTower Advisors LLC acquired a new stake in shares of OrthoPediatrics Corp. (NASDAQ:KIDS) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 11,551 shares of the company’s stock, valued at approximately $268,000.

A number of other hedge funds have also recently bought and sold shares of KIDS. Charles Schwab Investment Management Inc. lifted its stake in shares of OrthoPediatrics by 2.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 132,434 shares of the company’s stock worth $3,590,000 after purchasing an additional 2,661 shares during the period. Quantbot Technologies LP increased its stake in OrthoPediatrics by 42.2% in the third quarter. Quantbot Technologies LP now owns 5,773 shares of the company’s stock valued at $157,000 after purchasing an additional 1,712 shares during the last quarter. BNP Paribas Financial Markets lifted its position in OrthoPediatrics by 125.1% during the third quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company’s stock worth $94,000 after buying an additional 1,929 shares during the period. Centiva Capital LP acquired a new stake in OrthoPediatrics in the 3rd quarter worth about $319,000. Finally, Portolan Capital Management LLC grew its holdings in OrthoPediatrics by 66.2% in the 3rd quarter. Portolan Capital Management LLC now owns 308,099 shares of the company’s stock valued at $8,353,000 after buying an additional 122,770 shares during the period. Institutional investors and hedge funds own 69.05% of the company’s stock.

OrthoPediatrics Stock Performance

NASDAQ KIDS opened at $26.31 on Thursday. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.17 and a quick ratio of 3.68. OrthoPediatrics Corp. has a 1-year low of $21.02 and a 1-year high of $35.99. The firm has a market capitalization of $638.99 million, a P/E ratio of -21.39 and a beta of 1.16. The business’s 50-day simple moving average is $24.64 and its 200-day simple moving average is $25.11.

OrthoPediatrics (NASDAQ:KIDS) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. The firm had revenue of $52.67 million for the quarter, compared to analysts’ expectations of $51.16 million. During the same period in the previous year, the company posted ($0.23) earnings per share. Equities analysts predict that OrthoPediatrics Corp. will post -0.93 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on KIDS. Needham & Company LLC reiterated a “buy” rating and set a $42.00 price objective on shares of OrthoPediatrics in a report on Wednesday, March 5th. Stifel Nicolaus cut their price target on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, March 5th. Finally, Truist Financial decreased their price target on shares of OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th.

Insider Activity at OrthoPediatrics

In other news, CFO Fred Hite sold 6,443 shares of the company’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $160,172.98. Following the completion of the transaction, the chief financial officer now directly owns 207,989 shares in the company, valued at approximately $5,170,606.54. This represents a 3.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Daniel J. Gerritzen sold 5,310 shares of the firm’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $132,006.60. Following the sale, the general counsel now directly owns 110,767 shares of the company’s stock, valued at approximately $2,753,667.62. The trade was a 4.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 23,732 shares of company stock worth $589,978. Corporate insiders own 31.80% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.